Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell–mediated immunotherapy
J. Clin. Invest. Jonathan D. Silk, et al. 114:1800
doi:10.1172/JCI22046 [Go to this article.]

Problems with a PDF?